Tufts University School of Medicine

eClinical Solutions Advances Modern Digital Trials at Engage 2023 Conference

Retrieved on: 
Thursday, November 9, 2023
Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Artificial Intelligence, Practice Management, Research, Software, Data Analytics, Health Technology, Science, Data Management, Clinical Trials, Cloud, Drug development, Digital, SCE, Intelligence, Biogen, BioNTech, PwC, The Newbury Boston, Snowflake, IDC, Organization, Biometrics, Multimedia, Tufts University School of Medicine, Clinical data management, BioMarin Pharmaceutical, Medicine, Tufts Center for the Study of Drug Development, AI, Patient, Disruptive innovation, Automation

eClinical Solutions , a global provider of digital clinical software and services, will bring together prominent clinical development leaders on Thursday, November 16 and Friday, November 17 for its fifth annual client and partner conference, Engage 2023.

Key Points: 
  • eClinical Solutions , a global provider of digital clinical software and services, will bring together prominent clinical development leaders on Thursday, November 16 and Friday, November 17 for its fifth annual client and partner conference, Engage 2023.
  • Taking place at The Newbury Boston, Engage 2023 includes nearly 280 attendees representing 60 life science organizations, and features five corporate sponsors including Halloran Consulting, PwC, Flatiron, LumaBridge, and Snowflake.
  • He will share recommendations for advancing healthcare and life science digital transformation and innovation, including the AI-embedded components of a modern end-to-end digital data blueprint that delivers and demonstrates analytics value at scale.
  • For more information about Engage and to see the agenda, please visit: www.eclinicalsol.com/event/elluminate-engage/ .

The Galien Foundation Honors 2023 Prix Galien Award Recipients

Retrieved on: 
Friday, October 27, 2023
American Cancer Society, Physiology, Medical genetics, Fred Hutchinson Cancer Research Center, Health technology, P. Roy Vagelos, Peace Corps, Incubator, University of Washington, NASA, Merck, Prix, Creativity, Tufts University School of Medicine, Koch Institute, Endeavour, MIT Jameel Clinic, Digital health, National Aeronautic Association, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Human Genome Sciences, African, ARD International Music Competition, Patient, Doctor of Philosophy, Nursing, Pharmaceutical industry, Biophysics, Biology

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year's award winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Product for Rare/Orphan Diseases," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity" and "Best Startup."

Key Points: 
  • "We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry," said Bruno Cohen, Chairman of The Galien Foundation.
  • "Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare."
  • The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement.
  • With chapters in 14 countries and Africa, and an inaugural chapter being established in India in 2024, Prix Galien is regarded worldwide as the equivalent of the Nobel Prize for the life science industry.

Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions

Retrieved on: 
Wednesday, October 25, 2023
Potsdam Institute for Climate Impact Research, Gastroenterology, FDA, Research, Oregon Health & Science University, United States Department of the Air Force, Obesity, General Social Care Council, Prevalence, Biological therapy for inflammatory bowel disease, Liver disease, Paulinum (University of Leipzig), ChromeOS, CPI, Tufts University School of Medicine, AGAF, Growth, Disease, St George's Hospital, NASH, University, KOL, Internal medicine, Icahn School of Medicine at Mount Sinai, Air force, Brooke Army Medical Center, DURHAM, FACP, FACG, Hepatology, Veteran, Patient, MASH, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, MD, Velocity

DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

Key Points: 
  • Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
  • With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
  • Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
  • Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.

Bay Area Lyme Foundation ELA Winner Uses Metabolic Modeling to Predict 77 Unique Drug Targets in Lyme Disease Bacterium

Retrieved on: 
Thursday, October 19, 2023
Linda, Lyme disease, Therapy, Doctor of Philosophy, ELA, Research, Enzyme, Drug development, Tufts University School of Medicine, Learning, Borrelia burgdorferi, M-Systems, Gene, Culture, Patient, Map, Infection, Pharmaceutical industry, Vaccine

PORTOLA VALLEY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, today announced the findings of a study identifying new essential gene and enzyme drug targets in Lyme disease bacterium, which resulted, in-part, from a grant provided to Peter Gwynne, one of Bay Area Lyme Foundation’s 2022 Emerging Leader Award (ELA) winners.

Key Points: 
  • PORTOLA VALLEY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, today announced the findings of a study identifying new essential gene and enzyme drug targets in Lyme disease bacterium, which resulted, in-part, from a grant provided to Peter Gwynne, one of Bay Area Lyme Foundation’s 2022 Emerging Leader Award (ELA) winners.
  • Published in the peer-reviewed journal mSystems, the study uses the most comprehensive metabolic modeling to date to predict 77 unique drug targets in Borrelia burgdorferi, the bacterium that causes Lyme disease — a condition affecting nearly 500,000 new patients annually.
  • “Lyme disease is often treated using long courses of antibiotics, which can cause side effects for patients and risks the evolution of antimicrobial resistance.
  • “There is a desperate need for therapeutics that can more effectively and precisely treat Lyme disease,” said Linda Giampa, executive director of the Bay Area Lyme Foundation.

Study Reveals the Need to Expand Maternal Mortality Categorization Beyond Pregnancy-Related Deaths

Retrieved on: 
Wednesday, October 25, 2023
Research, Opioid use disorder, Comorbidity, Maternal health, Department of Obstetrics and Gynecology (Massachusetts General Hospital), SMM, MPH, Black Maternal Health Caucus, Disease, Massachusetts Department of Public Health, Public health, Mortality, Obstetrics and gynaecology, University of California, Boston University School of Public Health, Tufts University School of Medicine, Death, Reproductive Sciences, Hospital, Risk, Pregnancy, University, NIH, Public, ER, Dietary supplement, Birth control, Gynaecology, Doctor of Philosophy, Obstetrics

BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large. Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019. It also identified four times as many pregnancy-associated deaths than pregnancy-related ones and a high rate of hospital contacts (hospital admission, observational stays, and ER visits) for those who ultimately died during pregnancy through one year postpartum.

Key Points: 
  • New Research Shows Prior Hospitalization, Severe Maternal Morbidity, and Opioid Use Disorder Were Key Contributors to Pregnancy-Associated Deaths in Massachusetts from 2002 to 2019.
  • BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large.
  • Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019.
  • There is a clear need to expand the focus of maternal mortality to the much larger group of pregnancy-associated deaths to understand the risk factors and events that lead to many of these preventable deaths."

The Inner Circle Acknowledges, Abraham Bornstein as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields

Retrieved on: 
Friday, October 13, 2023
Multimedia, Weill Cornell Medicine, Internal medicine, Physiology, Student, Public, Boston University, American College, Circulatory system, American College of Cardiology, Medicine, American Heart Association, American Board of Commissioners for Foreign Missions, Tufts University School of Medicine, Education, Maharishi International University, American Board of Internal Medicine, Inner circle, Nursing, Biology, Cardiology

NEW YORK, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Abraham Bornstein is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields.

Key Points: 
  • NEW YORK, Oct. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Abraham Bornstein is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the Cardiovascular and Physiology Fields.
  • Dr. Bornstein pursued higher education at Boston University where he earned a Bachelor of Arts degree in Biology in 1969.
  • He then attended Tufts University School of Medicine in 1973 obtaining a Doctor of Medicine degree in 1973.
  • He has received many accolades during his career, including multiple teaching awards from Stanford Hospital and Practice.

HelpMeSee announces Dr. Bonnie An Henderson as president and CEO

Retrieved on: 
Tuesday, October 10, 2023
Ueltschi, Dartmouth College, Refractive surgery, Society, Defense, Medicine, Tufts University School of Dental Medicine, Visual impairment, Tufts University School of Medicine, Department of Defence, Paratriathlon, Journal, American Society of Cataract and Refractive Surgery, Cataract, Harvard Medical School, Publication, Massachusetts Eye and Ear, Geisel School of Medicine, Journal of Refractive Surgery, Woman, Management, Ophthalmology

JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.

Key Points: 
  • JERSEY CITY, N.J., Oct. 10, 2023 /PRNewswire/ -- HelpMeSee, the global mission to end cataract blindness by vastly expanding access to high quality, affordable treatment, has elected Dr. Bonnie An Henderson as its President and CEO effective immediately.
  • Dr. Henderson is an internationally recognized expert in cataract and refractive surgery, with a distinguished career that includes past presidency of the American Society of Cataract and Refractive Surgery.
  • Dr. Bonnie An Henderson said, "My entire professional career as a cataract surgeon and educator has led me to HelpMeSee.
  • Jim Ueltschi, founder, and chairman of the board of directors at HelpMeSee stated that "We are delighted and flattered that Bonnie is our CEO and President.

The Nation’s Largest Private Academic Plastic Surgery Practice Continues to Expand with the Addition of Two Surgeons

Retrieved on: 
Wednesday, September 20, 2023
Tufts University, Icahn School of Medicine at Mount Sinai, Tufts University School of Medicine, Surgeon, Education, Rhinoplasty, Cancer, Head, Breast, General surgery, History, Harvard University, Harvard Medical School, Tufts University School of Dental Medicine, Running, Cornell University, Patient, Mount Sinai School, Memorial Sloan Kettering Cancer Center, Medical school, Biology, New York Presbyterian Church of Long Island City, New York, Growth, United, Health, Dana–Farber Cancer Institute, Columbus Circle, Medical device, Dentistry, Microsurgery, Medicine

Dr. Samson, an internationally recognized plastic surgeon, has been practicing in New York City for nearly 20 years, and specializes in both aesthetic and reconstructive breast surgery.

Key Points: 
  • Dr. Samson, an internationally recognized plastic surgeon, has been practicing in New York City for nearly 20 years, and specializes in both aesthetic and reconstructive breast surgery.
  • “Our surgeons, both past and present, are known for pioneering and performing the most advanced reconstructive and cosmetic surgical procedures available.
  • In addition to expertise in all areas of plastic surgery, Dr. Samson is known as a specialist in both aesthetic and reconstructive breast surgery, and he is often called on to manage complex revision breast surgery procedures.
  • Dr. Jason Clain is a Harvard-trained plastic surgeon specializing in both reconstructive and aesthetic plastic surgery.

Regeneron Announces Updates to Board of Directors

Retrieved on: 
Friday, September 8, 2023
Product management, Yale University, IBM, Senior, Doctor of Philosophy, Information technology, Stanford University, GV, Biotechnology, State university system, Genentech, General partnership, Medicine, GV (company), IBM System/360 Model 67, Translation, Tufts University School of Engineering, Office of American Innovation, Agios, Tufts Medical Center, Patient, National Council, Clinical research, Takeda Oncology, Hematology, Physics, Artificial intelligence, Knowledge, CIO, Research, Tufts University School of Medicine, Food Technology (magazine), IBM Research, Management, Pharmaceutical industry, Science, Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s Board of Directors effective September 8, 2023.

Key Points: 
  • TARRYTOWN, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s Board of Directors effective September 8, 2023.
  • “I am thrilled to join Regeneron’s Board of Directors,” said Dr. Guarini.
  • “It has been a great privilege to be a member of Regeneron’s Board for close to 12 years,” said Dr. Tessier-Lavigne.
  • We also thank Marc for his many outstanding contributions and long-term commitment to Regeneron, and we wish him well in his next steps.”

Hoag Recruits Renowned Physician and Researcher from Dartmouth to Lead Hoag Neuro-Oncology Program

Retrieved on: 
Wednesday, August 30, 2023
Abstract, Surgeon, Tufts University School of Medicine, University, Hoag, Internal medicine, UNC, AUC, Endure to Cure Foundation, UNC Health Care, Duke University School of Medicine, Meningioma, Cancer, Research, Oncology, Immunotherapy, Glioblastoma, American College of Physicians, Radiation, Dartmouth, Dartmouth Cancer Center, Hematology, Geisel School of Medicine, Management, University of Washington School of Medicine, Diagnosis, Neuro, Cancer Management and Research, University of Missouri–Kansas City School of Medicine, American College, Medical imaging, Nursing, Physician, Brain, Medicine

NEWPORT BEACH, Calif. , Aug. 30, 2023 /PRNewswire/ -- Hoag is proud to announce that Simon Khagi, M.D., F.A.C.P., a renowned, triple board-certified medical oncologist and neuro-oncologist specializing in primary and metastatic brain cancers and spinal cord tumors, has joined the Hoag Family Cancer Institute as the director of neuro-oncology.

Key Points: 
  • Under Dr. Khagi's leadership, Hoag's Brain & Spine Tumor program will further its offerings in diagnosis, management and research, rivaling major academic medical centers.
  • "Dr. Khagi brings specialized expertise and research accomplishments that few physicians in the country can offer," said Burton Eisenberg, M.D., Grace E. Hoag Executive Medical Director Endowed Chair, Hoag Family Cancer Institute.
  • "His unique expertise in neuro-oncology is another example of how Hoag is highly committed to bringing the highest level of talent and innovation to our community."
  • Dr. Khagi joins Hoag after serving as regional medical director at Dartmouth Cancer Center in southern New Hampshire.